These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1725068)

  • 1. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Clin Pharmacol Ther; 1991 Oct; 50(4):429-36. PubMed ID: 1914379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro stability of a tissue-type plasminogen activator mutant, BM 06.022, in human plasma.
    Rijken DC; Groeneveld E; Barrett-Bergshoeff MM
    Thromb Haemost; 1994 Dec; 72(6):906-11. PubMed ID: 7740462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
    Martin U; Sponer G; Strein K
    Drug Metab Dispos; 1993; 21(2):236-41. PubMed ID: 8097691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects.
    Tanswell P; Seifried E; Su PC; Feuerer W; Rijken DC
    Clin Pharmacol Ther; 1989 Aug; 46(2):155-62. PubMed ID: 2503283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
    Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB
    J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Res; 1991 May; 62(3):137-46. PubMed ID: 1909815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recombinant tissue-type plasminogen activator: pharmacokinetics and effect on the hemostasis system of the human].
    Seifried E; Böck F; Tanswell P; Rijken DC; Kluft C; Heimpel H
    Klin Wochenschr; 1988; 66 Suppl 12():40-9. PubMed ID: 2450222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.
    de Boer A; Kluft C; Gerloff J; Dooijewaard G; Günzler WA; Beier H; van der Meer FJ; Cohen AF
    Thromb Haemost; 1993 Aug; 70(2):320-5. PubMed ID: 8236142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat.
    Bloom JC; Sellers TS; Gries GC; Wheeldon EB; O'Brien SR; Lewis HB
    Thromb Haemost; 1988 Oct; 60(2):271-9. PubMed ID: 3146143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic effect of a particular glycosaminoglycan (endoglycan) per os on normals and in patients with chronic artery disease.
    Patrassi GM; Veronesi A; Sartori MT; Viero ML; Boeri G; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):369-76. PubMed ID: 1703105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
    Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
    Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Lill H; Rudolph R; Sponer G; Stern A; Strein K
    Z Kardiol; 1990; 79 Suppl 3():167-70. PubMed ID: 2129142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.